These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

740 related articles for article (PubMed ID: 24014826)

  • 1. Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model.
    Hamdani N; Franssen C; Lourenço A; Falcão-Pires I; Fontoura D; Leite S; Plettig L; López B; Ottenheijm CA; Becher PM; González A; Tschöpe C; Díez J; Linke WA; Leite-Moreira AF; Paulus WJ
    Circ Heart Fail; 2013 Nov; 6(6):1239-49. PubMed ID: 24014826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct Endothelial Cell Responses in the Heart and Kidney Microvasculature Characterize the Progression of Heart Failure With Preserved Ejection Fraction in the Obese ZSF1 Rat With Cardiorenal Metabolic Syndrome.
    van Dijk CG; Oosterhuis NR; Xu YJ; Brandt M; Paulus WJ; van Heerebeek L; Duncker DJ; Verhaar MC; Fontoura D; Lourenço AP; Leite-Moreira AF; Falcão-Pires I; Joles JA; Cheng C
    Circ Heart Fail; 2016 Apr; 9(4):e002760. PubMed ID: 27056881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arterial Remodeling and Dysfunction in the ZSF1 Rat Model of Heart Failure With Preserved Ejection Fraction.
    Leite S; Cerqueira RJ; Ibarrola J; Fontoura D; Fernández-Celis A; Zannad F; Falcão-Pires I; Paulus WJ; Leite-Moreira AF; Rossignol P; López-Andrés N; Lourenço AP
    Circ Heart Fail; 2019 Jul; 12(7):e005596. PubMed ID: 31525070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deranged myofilament phosphorylation and function in experimental heart failure with preserved ejection fraction.
    Hamdani N; Bishu KG; von Frieling-Salewsky M; Redfield MM; Linke WA
    Cardiovasc Res; 2013 Mar; 97(3):464-71. PubMed ID: 23213108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased passive stiffness promotes diastolic dysfunction despite improved Ca2+ handling during left ventricular concentric hypertrophy.
    Røe ÅT; Aronsen JM; Skårdal K; Hamdani N; Linke WA; Danielsen HE; Sejersted OM; Sjaastad I; Louch WE
    Cardiovasc Res; 2017 Aug; 113(10):1161-1172. PubMed ID: 28472418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Both male and female obese ZSF1 rats develop cardiac dysfunction in obesity-induced heart failure with preserved ejection fraction.
    Nguyen ITN; Brandt MM; van de Wouw J; van Drie RWA; Wesseling M; Cramer MJ; de Jager SCA; Merkus D; Duncker DJ; Cheng C; Joles JA; Verhaar MC
    PLoS One; 2020; 15(5):e0232399. PubMed ID: 32374790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Afterload-induced diastolic dysfunction contributes to high filling pressures in experimental heart failure with preserved ejection fraction.
    Leite S; Rodrigues S; Tavares-Silva M; Oliveira-Pinto J; Alaa M; Abdellatif M; Fontoura D; Falcão-Pires I; Gillebert TC; Leite-Moreira AF; Lourenço AP
    Am J Physiol Heart Circ Physiol; 2015 Nov; 309(10):H1648-54. PubMed ID: 26408538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.
    Paulus WJ; Tschöpe C
    J Am Coll Cardiol; 2013 Jul; 62(4):263-71. PubMed ID: 23684677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin.
    Zile MR; Baicu CF; Ikonomidis JS; Stroud RE; Nietert PJ; Bradshaw AD; Slater R; Palmer BM; Van Buren P; Meyer M; Redfield MM; Bull DA; Granzier HL; LeWinter MM
    Circulation; 2015 Apr; 131(14):1247-59. PubMed ID: 25637629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetes-Induced Cardiomyocyte Passive Stiffening Is Caused by Impaired Insulin-Dependent Titin Modification and Can Be Modulated by Neuregulin-1.
    Hopf AE; Andresen C; Kötter S; Isić M; Ulrich K; Sahin S; Bongardt S; Röll W; Drove F; Scheerer N; Vandekerckhove L; De Keulenaer GW; Hamdani N; Linke WA; Krüger M
    Circ Res; 2018 Jul; 123(3):342-355. PubMed ID: 29760016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Geranylgeranylacetone reduces cardiomyocyte stiffness and attenuates diastolic dysfunction in a rat model of cardiometabolic syndrome.
    Waddingham MT; Sequeira V; Kuster DWD; Dal Canto E; Handoko ML; de Man FS; da Silva Gonçalves Bós D; Ottenheijm CA; Shen S; van der Pijl RJ; van der Velden J; Paulus WJ; Eringa EC
    Physiol Rep; 2023 Nov; 11(22):e15788. PubMed ID: 37985159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acetylation and phosphorylation changes to cardiac proteins in experimental HFpEF due to metabolic risk reveal targets for treatment.
    Koser F; Hobbach AJ; Abdellatif M; Herbst V; Türk C; Reinecke H; Krüger M; Sedej S; Linke WA
    Life Sci; 2022 Nov; 309():120998. PubMed ID: 36179815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of diastolic dysfunction in heart failure with a preserved ejection fraction: If it's not one thing it's another.
    LeWinter MM; Meyer M
    Circ Heart Fail; 2013 Nov; 6(6):1112-5. PubMed ID: 24255055
    [No Abstract]   [Full Text] [Related]  

  • 14. α-B Crystallin Reverses High Diastolic Stiffness of Failing Human Cardiomyocytes.
    Franssen C; Kole J; Musters R; Hamdani N; Paulus WJ
    Circ Heart Fail; 2017 Mar; 10(3):e003626. PubMed ID: 28242778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spectral transfer function analysis of respiratory hemodynamic fluctuations predicts end-diastolic stiffness in preserved ejection fraction heart failure.
    Abdellatif M; Leite S; Alaa M; Oliveira-Pinto J; Tavares-Silva M; Fontoura D; Falcão-Pires I; Leite-Moreira AF; Lourenço AP
    Am J Physiol Heart Circ Physiol; 2016 Jan; 310(1):H4-13. PubMed ID: 26475584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited synergy of obesity and hypertension, prevalent risk factors in onset and progression of heart failure with preserved ejection fraction.
    Brandt MM; Nguyen ITN; Krebber MM; van de Wouw J; Mokry M; Cramer MJ; Duncker DJ; Verhaar MC; Joles JA; Cheng C
    J Cell Mol Med; 2019 Oct; 23(10):6666-6678. PubMed ID: 31368189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic Sildenafil Therapy in the ZSF1 Obese Rat Model of Metabolic Syndrome and Heart Failure With Preserved Ejection Fraction.
    Leite S; Moreira-Costa L; Cerqueira R; Sousa-Mendes C; Angélico-Gonçalves A; Fontoura D; Vasques-Nóvoa F; Leite-Moreira AF; Lourenço AP
    J Cardiovasc Pharmacol Ther; 2021 Nov; 26(6):690-701. PubMed ID: 34328815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting MuRF1 by small molecules in a HFpEF rat model improves myocardial diastolic function and skeletal muscle contractility.
    Adams V; Schauer A; Augstein A; Kirchhoff V; Draskowski R; Jannasch A; Goto K; Lyall G; Männel A; Barthel P; Mangner N; Winzer EB; Linke A; Labeit S
    J Cachexia Sarcopenia Muscle; 2022 Jun; 13(3):1565-1581. PubMed ID: 35301823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimentally Increasing the Compliance of Titin Through RNA Binding Motif-20 (RBM20) Inhibition Improves Diastolic Function In a Mouse Model of Heart Failure With Preserved Ejection Fraction.
    Methawasin M; Strom JG; Slater RE; Fernandez V; Saripalli C; Granzier H
    Circulation; 2016 Oct; 134(15):1085-1099. PubMed ID: 27630136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linagliptin prevents left ventricular stiffening by reducing titin cleavage and hypophosphorylation.
    Cuijpers I; Papageorgiou AP; Carai P; Herwig M; Mügge A; Klein T; Hamdani N; Jones EAV; Heymans S
    J Cell Mol Med; 2021 Jan; 25(2):729-741. PubMed ID: 33295687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.